• More Than Teeth
  • Posts
  • Sodium Channel Blockers: A New Era in Dental Pain Management?

Sodium Channel Blockers: A New Era in Dental Pain Management?

Where Dentistry Meets Whole-Body Health Michael Bennett, DDS, PhD & Cathy Bennett, MS, NBCHWC

March 24, 2026

This is More Than Teeth. The newsletter that helps dental sleep professionals get 1% better every week.

Busy week? Just read the Key Takeaways — 60 seconds, and you're caught up.

Good Morning,

I recently spoke with an orthopedic surgeon about a mutual patient preparing for a hip replacement. The topic shifted, as it often does, to pain control.

But this time, something different came up.

A new non-opioid pain medication that works outside the brain.

That caught my attention.

Because in dentistry, we live in the world of acute pain, post-op discomfort, extractions, implants, endo, and we’ve long relied on a predictable combination:

Acetaminophen + ibuprofen

Effective. Evidence-based. Familiar.

But what if a new option is emerging, one that works earlier in the pain pathway?

Let’s talk about it.

Key Takeaways (60 seconds)

  • A new class of analgesics, NaV1.8 sodium channel blockers (e.g., suzetrigine), targets pain in the peripheral nervous system, not the brain, and is better for patients with central apnea.

  • Dentists can prescribe it, but adoption is early

  • It does not prolong local anesthesia, but may smooth post-op pain

  • No true head-to-head dental studies vs. ibuprofen + acetaminophen

  • Cost and access are currently the biggest barriers

  • Coupon programs may reduce the cost to ~$30 if processed correctly

5-minute read👇

The Big Idea: Treat Pain Before It Reaches the Brain

Traditional analgesics:

  • NSAIDs → inflammation

  • Acetaminophen → central modulation

  • Opioids → central receptors

Suzetrigine is different.

It blocks NaV1.8 sodium channels in peripheral pain fibers, reducing pain signaling before it reaches the CNS.

Less central effect. More targeted physiology.

Why This Matters in Dentistry

Dentistry focuses on treating specific, intense pain right where it starts, which makes this approach very important. Possible benefits: Targets specific areas. Does not lead to addiction. Reduces the need for opioids. It has few side effects on the central nervous system, especially for patients with central apnea.

Can Dentists Prescribe It?

Yes, within scope.

But practically:

  • It’s very new (FDA 2025)

  • Limited familiarity with dentistry

  • Coverage and cost are still evolving

Clinical Insight: Does It Enhance Local Anesthesia?

In short, no. While both local anesthetics and Suzetrigine block sodium channels, they do so in different ways. Local anesthetics completely block nerve signals, acting like an "off switch." Suzetrigine, on the other hand, modulates pain signals, working like a "volume control."

In practice, Suzetrigine does not extend numbness or deepen anesthesia. However, it may help reduce pain after surgery as the anesthesia fades, providing a smoother transition rather than prolonged numbness.

The Real-World Question: Cost & Access

This is where things get very practical for your patients.

Current Reality (Early 2026)

  • As a new branded medication, suzetrigine is:

    • Expensive without coverage (often several hundred dollars+)

    • Not yet widely included on formularies

Insurance Coverage

  • Variable and often limited early on

  • Some plans may:

    • Require prior authorization

    • Deny coverage initially

  • Expect lag time before widespread adoption

What About the $30 Coupon?

Yes, this is real and important.

Many patients can access manufacturer savings programs that:

Reduce cost to ~$30 per prescription

BUT (this is key):

Success depends on the pharmacy knowing how to process it.

Practical Tips for Your Team

  • Tell patients:
    👉 “Ask your pharmacy if they can apply the manufacturer savings card for Journavx (suzetrigine).”

  • If issues arise:

    • Try larger retail pharmacies (CVS, Walgreens, etc.)

    • Independent pharmacies may need guidance

  • Patients may need:

    • A coupon card or BIN/PCN info (often available on the manufacturer's website)

Clinical Perspective: Where Might This Fit?

Right now:

  • Patients who can’t take NSAIDs

  • Patients avoiding opioids

  • Cases of moderate–severe acute pain

But adoption will likely depend heavily on:

👉 Cost + ease of access

A Bigger Shift Is Happening

This isn’t just a new drug.

It’s a shift:

➡️ From central suppression
➡️ To targeted peripheral modulation

Just like airway-centered care:

Treat the source. Respect physiology. Support healing.

References & Resources

Sodium Channel Blockers / Suzetrigine

Dental Pain Management (Current Standard of Care)

Savings & Patient Access (Important for Clinical Use)

  • Official Manufacturer Website (Journavx – Suzetrigine)
    👉 Start here for savings programs and prescribing info
    https://www.journavx.com

  • Manufacturer Savings / Copay Program (if available in your region)
    👉 Patients or pharmacies can search “Journavx savings card” on this site

  • GoodRx (price comparison + pharmacy coupons)
    https://www.goodrx.com

Clinical Context: Dentistry & Systemic Health

  • American Dental Association Policy on SRBD Screening (2017)

Final Thought

Dentistry has already led the way in reducing opioid prescriptions.

This next wave, precision, peripherally targeted analgesia, may be the next step.

Not a replacement.
But an expansion.

And for patients seeking effective pain control without central side effects, that matters.

Until next week,
— Dr. Michael & Cathy Bennett
More Than Teeth | A Mission for Generational Health

For more podcasts and great information, check out our website here

Reply

or to participate.